Published in AIDS on July 25, 2003
Protease expression by microorganisms and its relevance to crucial physiological/pathological events. World J Biol Chem (2011) 0.76
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest (2010) 2.92
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica (2002) 1.72
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr (2007) 1.38
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol (2006) 1.30
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr (2003) 1.25
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res (2007) 1.23
Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown) (2009) 1.16
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica (2008) 1.16
Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg Infect Dis (2004) 1.14
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther (2005) 1.04
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med (2002) 1.03
Analysis of variation in tandem repeats in the intron of the major surface glycoprotein expression site of the human form of Pneumocystis carinii. J Infect Dis (2002) 1.00
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur J Clin Pharmacol (2005) 0.99
Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. J Infect Dis (2002) 0.99
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother (2010) 0.99
How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab (2010) 0.98
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother (2005) 0.96
Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother (2012) 0.95
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr (2003) 0.95
Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother (2009) 0.95
Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr (2008) 0.94
Restriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jirovecii isolates. J Infect Dis (2009) 0.94
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst (2006) 0.93
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother (2010) 0.91
Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr (2007) 0.90
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens. Ther Drug Monit (2008) 0.90
Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther (2003) 0.90
Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharmacol (2013) 0.89
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther (2005) 0.89
Sex differences in nevirapine disposition in HIV-infected patients. AIDS (2003) 0.87
Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet (2014) 0.86
Assessment of in vivo genotoxicity of the rodent carcinogen furan: evaluation of DNA damage and induction of micronuclei in mouse splenocytes. Mutagenesis (2009) 0.86
Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon (2011) 0.85
Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. Ther Drug Monit (2014) 0.85
Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther (2005) 0.85
A Comparison of Differences Between the Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion: A Prospective, Randomized, Multicenter, Double-Blind Controlled Trial. Anesth Analg (2015) 0.85
Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS (2002) 0.84
Morphine metabolism, transport and brain disposition. Metab Brain Dis (2011) 0.84
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol (2005) 0.84
High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology (2007) 0.84
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res Hum Retroviruses (2007) 0.83
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS Patient Care STDS (2008) 0.83
Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemother (2003) 0.83
Direct and delayed X-ray-induced DNA damage in male mouse germ cells. Environ Mol Mutagen (2012) 0.83
Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother (2012) 0.83
A case of Pneumocystis jiroveci pneumonia in X-linked agammaglobulinaemia treated with immunosuppressive therapy: a lesson for immunologists. Int Arch Allergy Immunol (2006) 0.82
Pharmacokinetics, pharmacodynamics and clinical use of valganciclovir in newborns with symptomatic congenital cytomegalovirus infection. Curr Drug Metab (2013) 0.82
Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res (2012) 0.81
cART durability and causes for treatment switching or discontinuation in HIV-positive patients older than 50 years of age. J Acquir Immune Defic Syndr (2010) 0.80
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit (2008) 0.80
Assessment of the in vivo genotoxicity of vanadate: analysis of micronuclei and DNA damage induced in mice by oral exposure. Toxicol Lett (2005) 0.80
Usefulness of serial determination of Aspergillus galactomannan in the diagnosis and management of invasive aspergillosis in an AIDS patient with non-Hodgkin lymphoma. Mycoses (2011) 0.80
Toxic and genotoxic effects of oral administration of furan in mouse liver. Mutagenesis (2010) 0.80
Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology (2005) 0.79
Cutaneous silent period in human immunodeficiency virus-related peripheral neuropathy. J Peripher Nerv Syst (2004) 0.79
Exposure to radiofrequency radiation (900 MHz, GSM signal) does not affect micronucleus frequency and cell proliferation in human peripheral blood lymphocytes: an interlaboratory study. Radiat Res (2006) 0.79
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents (2006) 0.79
Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Br J Clin Pharmacol (2010) 0.79
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. J Antimicrob Chemother (2011) 0.79
Genotypic resistance tests for the management of the HIV-infected pregnant woman. Scand J Infect Dis Suppl (2003) 0.78
HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr (2003) 0.78
Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose/body mass index. AIDS (2002) 0.78
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol (2005) 0.78
Innovative non-animal testing strategies for reproductive toxicology: the contribution of Italian partners within the EU project ReProTect. Ann Ist Super Sanita (2011) 0.78
Evaluation of genotoxic effect of low level 50 Hz magnetic fields on human blood cells using different cytogenetic assays. Bioelectromagnetics (2004) 0.78
ReProComet: a new in vitro method to assess DNA damage in mammalian sperm. Toxicol Sci (2007) 0.78
Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther (2014) 0.78
Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS (2007) 0.77
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. Leuk Lymphoma (2013) 0.77
Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. Ann Pharmacother (2009) 0.77
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. J Acquir Immune Defic Syndr (2009) 0.77
Feasibility of assessing autonomic dysregulation at a distance: the case of the HIV-positive patient. Telemed J E Health (2007) 0.77
Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit (2011) 0.77
Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica (2011) 0.77